ROSEN, NATIONAL TRIAL LAWYERS, encourages Fulcrum Therapeutics, Inc….
NEW YORK, May 27, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Fulcrum Therapeutics Inc. FULC between March 3, 2022 and March 8, 2023, both dates inclusive (the “Instruction Period”), the important June 27, 2023 Deadline for Lead Plaintiff. SO WHAT: If you purchased Fulcrum securities […]
Vertical Peak Completes Spin-Off of Neural Therapeutics – Vertical…
Vertical Peak Holdings Inc. SPLIF MJMJ And Neural Therapeutics Inc., closeded the spin out of Neural by a Scheme of Agreement under the British Columbia Business Corporations Act pursuant to the Amended and Restated Agreement dated February 24, 2023. Completion of the agreement plan The effective date of the agreement plan has been set for […]
Carmot Therapeutics Raises $150M in Series E Equity Funding…
–Proceeds to support the development of Carmot’s broad metabolic clinical pipeline, including two Phase 2 studies of CT-388, a once-weekly, dual GLP-1/GIP receptor modulator for obese adults with and without type 2 diabetes – – Carmot is also developing CT-868, a once-daily dual GLP-1/GIP receptor modulator for patients with type 1 diabetes, and CT-996, an […]
FTC Files Lawsuit to Stop Amgen’s Purchase of Horizon Therapeutics, Sending…
In a rare move to block a major pharmaceutical deal, the U.S. Federal Trade Commission would sue to stop it amgen inc AMGN $28 billion acquisition of Horizon Therapeutics PLC HZNP. Reuters reported that the FTC said Amgen could use its solid position to pressure insurance companies and pharmacy benefits managers into favorable terms on […]
ROSEN, TOP GLOBAL CONSULTANT, encourages Fulcrum Therapeutics to…
NEW YORK, May 13, 2023 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds buyers of Fulcrum Therapeutics Inc. securities, FULC between March 3, 2022 and March 8, 2023, both dates inclusive (the “Instruction Period”), the important June 27, 2023 Deadline for Lead Plaintiff. SO WHAT: If you purchased Fulcrum […]
Why Are Heron Therapeutics Shares Trading 34% Lower? Here are others…
winner GSI Technology, Inc. GSIT Shares are up 108% to $3.4207. GSI Technology is expected to report fourth fiscal quarter financial results after market close on May 16, 2023. ARS Pharmaceuticals, Inc. WARM Shares rose 82.8% to $8.27 after the company reported that the FDA Advisory Committee approved a positive benefit-risk assessment of […]
Stephen C. Glover, CEO of ZyVersa Therapeutics, attends…
ZyVersa is advancing a dynamic pipeline of drug candidates with multiple programs based on two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for the treatment of kidney disease and Inflammasome ASC Inhibitor IC 100 for the treatment of multiple CNS and other inflammatory diseases Mr. Glover welcomes one-on-one meetings with registered investors to discuss […]
Pliant Therapeutics Announces Positive Long-Term Data From…
Bexotegrast was well tolerated for up to 40 weeks of treatment without drug-related serious adverse events Combining bexotegrast with standard treatment reduced FVC decline by 80% relative to standard of care at week 24 alone 89% of bexotegrast-treated patients with an increase in FVC from baseline at week 12 maintained an increase at week 24 […]
Nicox’s Partner Ocumension Therapeutics Receives Priority Review…
press release Nicox’s partner, Ocumension Therapeutics, Receives Priority Review Status for ZERVIATE New Drug Application in China Nicox PArtner, occupation therapeutics, announced on April 26, 2023 that they had done so received priority review status for The Nah DCarpet AApplication for ZERVIATE in China Accelerates the CERVIATE® Admission and launchwhich are expected in China in […]
Autolus Therapeutics Announces Pivotal Phase 2 FELIX Trial of…
LONDON, April 27, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc AUTHa clinical-stage biopharmaceutical company developing next-generation programmed T-cell therapies, today announced that the summary of the pivotal Phase 2 FELIX study of obecabtagene-autoleucel (Obe-Cel) in relapsed/refractory ( r/r) adult B-cell acute lymphoblastic leukemia (ALL) has been selected for an oral presentation at the 2023 American […]